他克莫司软膏治疗白癜风的临床疗效及长期随访观察  

Long-term efficacy and safety of tacrolimus ointment in the treatment of vitiligo

作　　者：王晓艳[1] 徐前喜[1] 陈周[1] 常建民[2] 杜娟[1] 张建中[1] 

机构地区：[1]北京大学人民医院皮肤科,北京100044 [2]卫生部北京医院皮肤科,北京100730

出　　处：《临床皮肤科杂志》2010年第10期625-628,共4页Journal of Clinical Dermatology

摘　　要：目的:对前期已完成的他克莫司软膏治疗白癜风临床观察的患者进行随访,以获得他克莫司治疗白癜风长期的疗效及不良反应等资料。方法:采用调查问卷方式,对已完成前期观察并可配合问卷调查的患者进行随访。随访间期为试验结束后6～30个月。结果:46例入选患者中,34例(73.9%)完成随访研究。前期观察结束时,13例复色面积达到50%或以上,显效率为38.24%,总有效率为73.53%。随访时,7例(20.6%)病情加重,12例(35.3%)病情减轻。13例(38.2%)选择继续使用他克莫司,8例(23.5%)采用其他方法治疗。继续单用他克莫司80%有效,他克莫司联合治疗62.5%有效。随访中8例出现一过性不良反应,2周内可自行消退。7例出现后期不良反应(毛囊炎、过度色素沉着),数月后消退。结论:白癜风患者对他克莫司有一定认同度。停药复发后继续使用该药仍然有效。他克莫司早期及后期不良反应较轻。Objective： Aim of this study is to acquire the long-term efficacy and safety profile of topical tacrolimus in the treatment of vitiligo based on our prior clinical trials. Methods： A follow-up questionnaire was designed and performed after post-trial 6-30 months. Patients who had accomplished trials and were available for the questionnaire were included. Results： Forty-six patients were recruited and 34（73.9%） accomplished the follow-up study. Seven patients（ 20.6% ） were found aggravated at the time of follow-up while 12 patients （35.3%） extenuated. Twenty-one patients（61.7%） underwent the continued therapy, of whom, 13 patients（38.2%） continued tacrolimus therapy, 8 patients （23.5%） continued other therapies. The response rates for single and combination therapy were 80% and 62.5%, respectively. Eight patients had transient adverse events which could regress spontaneously after two weeks. Seven patients had late adverse events such as folliculitis and hyperpigmentation which could disappear after several months. Conclusions： Patients respond well to tacrolimus. Although some patients have aggravated after stopping using tacrolimus, reusing is still effective. Early and late adverse events are milder, which can disappear without influence of the appearance.

关 键 词：白癜风 他克莫司 临床疗效 不良反应 

分 类 号：R758.41[医药卫生—皮肤病学与性病学]